GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati
Fecha de publicación
2015Título de revista
EUROPEAN JOURNAL OF CANCER
Tipo de contenido
Artigo